Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 217

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 217
---
 tax rate applied to the year-to-date operating results adjusted for certain discrete tax items. 

The effective tax rate for the three and six months ended June 30, 2025 is primarily impacted by costs related to non-deductible stock-based compensation, non-deductible executive compensation and a non-U.S. valuation allowance. The effective tax rates for the three and six months ended June 30, 2024 include costs related to non-deductible stock-based 

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 51

compensation, primarily related to expired stock options, and non-deductible executive compensation, partially offset by tax credits. 

Liquidity and Capital Resources

Since our inception in 2006, we have devoted most of our cash resources to manufacturing, R&D and selling, general and administrative activities related to the development and commercialization of EXPAREL. In addition, we acquired ZILRETTA as part of the Flexion Acquisition in November 2021 and iovera° as part of the MyoScience Acquisition in April 2019. We are primarily dependent on the commercial success of EXPAREL and ZILRETTA. We have financed our operations primarily with the proceeds from the sale of convertible senior notes and other debt, common stock, product sales and collaborative licensing and milestone revenue. As of June 30, 2025, we had an accumulated deficit of $206.4 million, cash and cash equivalents and available-for-sale investments of $445.9 million and working capital of $432.4 million.

We expect that our cash and cash equivalents and available-for-sale investments on hand will be adequate to cover our short-term liquidity needs, and that we would be able to access other sources of financing should the need arise.

Summary of Cash Flows

The following table summarizes our cash flows from operating, investing and financing activities for the periods indicated (in thousands): Six Months EndedJune 30,Condensed Consolidated Statements of Cash Flows Data:20252024 Net cash provided by (used in):Operating activities$47,471 $102,337 Investing activities36,534 (30,745)Financing activities(60,499)22,163 Effect of exchange rate changes on cash and cash equivalents204 — Net increase in cash and cash equivalents$23,710 $93,755 

 Operating Activities

During the six months ended June